John P Burnier

This inventor holds 33 USPTO granted patents and 32 published patent applications, plus 6 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Genentech, Inc., Sarcode Bioscience Inc., Bipar Sciences, Inc.. Active years: 1989-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John P Burnier. Retrieved from https://idiyas.com/inventor/john-p-burnier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33 (Patent Applications = 32)

% Patents Active = 90.9

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 9)

Average Co-Inventor Count = 2.5

ph-index = 17

Forward Citations = 568(Granted Patents)

Company Filing History:

Sarcode Bioscience Inc.

Bausch + Lomb Ireland Limited

Novartis Pharmaceuticals Corporation

patents

Years Active: 1989-2026

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

Diabetic Retinopathy

Drug Design

Cancer Treatment

Peptidomimetics

Platelet Aggregation Inhibitors

Serine Protease Variants

Atrial Natriuretic Peptides

Growth Hormone Secretagogues

Biologically Active Polypeptides

Crystalline Pharmaceuticals

Eye Disorders

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12558350 - COMPOSITIONS AND METHODS FOR TREATMENT (2026-02-24),

2. 11028077 - Crystalline pharmaceutical and methods of preparation and use thereof (2021-06-08),

3. 10960087 - Compositions and methods for treatment of diabetic retinopathy (2021-03-30),

4. 10188641 - Compositions and methods for treatment (2019-01-29),

5. 9890141 - Crystalline pharmaceutical and methods of preparation and use thereof (2018-02-13),

6. 9447077 - Crystalline pharmaceutical and methods of preparation and use thereof (2016-09-20),

7. 9353088 - Crystalline pharmaceutical and methods of preparation and use thereof (2016-05-31),

8. 9045457 - Compositions and methods for treatment (2015-06-02),

9. 8927574 - Crystalline pharmaceutical and methods of preparation and use thereof (2015-01-06),

10. 8871935 - Crystalline pharmaceutical and methods of preparation and use thereof (2014-10-28),

11. 8592450 - Compositions and methods for treatment of eye disorders (2013-11-26),

12. 8378105 - Crystalline pharmaceutical and methods of preparation and use thereof (2013-02-19),

13. 8367701 - Crystalline pharmaceutical and methods of preparation and use thereof (2013-02-05),

14. 8168655 - Compositions and methods for treatment of eye disorders (2012-05-01),

15. 8143447 - Treatment of cancer (2012-03-27),

Title: John P Burnier: Innovator in Pharmaceutical Advancements

Introduction

John P Burnier is a notable inventor based in Pacifica, CA, with an impressive portfolio that includes 32 patents. His work primarily revolves around pharmaceutical innovations that aim to address critical medical conditions. His contributions have significant implications in the treatment of LFA-1 mediated diseases and diabetic retinopathy, showcasing his commitment to improving patient outcomes through scientific advancements.

Latest Patents

Among his latest patents, John has developed a novel crystalline pharmaceutical method that discloses various polymorphic forms, including Forms A, B, C, D, and E, of a compound that acts as a potent inhibitor of LFA-1. This innovation not only outlines methods of preparation but also explores its uses in addressing LFA-1 mediated diseases. Additionally, he has introduced compositions and methods specifically targeting the treatment of diabetic retinopathy. This invention describes the administration of LFA-1 antagonists following a diagnosis of diabetic retinopathy, potentially transforming the therapeutic landscape for this condition.

Career Highlights

John has had a distinguished career, contributing his expertise to prominent companies in the pharmaceutical industry. He has worked for Genentech, Inc., a leader in biotechnology, where he honed his skills in drug development and innovation. His tenure at Sarcode Bioscience Inc. further exemplifies his dedication to advancing medical research and treatments.

Collaborations

Throughout his career, John has collaborated with esteemed professionals such as Thomas Gadek and Robert S McDowell. These partnerships have undoubtedly enriched his work, fostering an environment of shared knowledge and innovation in the pharmaceutical field.

Conclusion

John P Burnier stands out as a remarkable inventor whose work has had a profound impact on the pharmaceutical industry. His latest innovations not only reflect his scientific acumen but also his dedication to addressing significant health challenges. With a strong foundation of patents and collaborations, he continues to pave the way for future advancements in medical treatments.

Profile summary based on public USPTO records.